Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$150.30 USD

150.30
680,430

+0.34 (0.23%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

ICON (ICLR) Gains From Strategic Deals, New Innovations

ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base

QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.

GE HealthCare's (GEHC) New Launch to Enhance Precision Care

GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.

Philips (PHG) Aids Diagnostic Imaging With Philips CT 5300

Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.

Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup

Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.

Urmimala Biswas headshot

5 Best PEG-Based GARP Stocks for Investors

Here are the five stocks that qualify our screening criteria ¿¿¿ RCL, DVA, F, FIS and ITRI.

Waters (WAT) Boosts LC Solutions Portfolio With New Software

Waters (WAT) unveils HPLC CONNECT software, bolstering its liquid chromatography solutions portfolio.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Bruker's (BRKR) New Launches Drive Growth Amid FX Woes

Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.

Here's Why Investors Should Hold Labcorp (LH) Stock for Now

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Charles River (CRL) Forges Collaboration With Wheeler Bio

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Ideas feature highlights: HCA Healthcare, DaVita and General Motors

HCA Healthcare, DaVita and General Motors have been highlighted in this Investment Ideas article.

Earnings Estimates Moving Higher for DaVita HealthCare (DVA): Time to Buy?

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Ethan Feller headshot

Markets Appear Vulnerable: Hideout in these 3 Top Ranked Defensive Stocks

There are a number of bearish catalysts brewing... is it time to rotate into these defensive names?

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.